(Q39859193)

15 September 2017

title

Reversibility and recurrence of IGF-IR-induced mammary tumors (English)

1 reference

15 September 2017

R A Jones

1

1 reference

15 September 2017

C I Campbell

2

1 reference

15 September 2017

G A Wood

3

1 reference

15 September 2017

J J Petrik

4

1 reference

15 September 2017

R A Moorehead

5

1 reference

15 September 2017

language of work or name

English

0 references

publication date

20 April 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

28

1 reference

15 September 2017

issue

21

1 reference

15 September 2017

page(s)

2152-2162

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2009.79

15 September 2017

exact match

0 references

cites work

Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II)

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

The insulin-like growth factor system and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Models, mechanisms and clinical evidence for cancer dormancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Endocrine-responsive breast cancer and strategies for combating resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Blockade of the type I somatomedin receptor inhibits growth of human breast cancer cells in athymic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

DeltaEF1 is a transcriptional repressor of E-cadherin and regulates epithelial plasticity in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

IGF-II mRNA and protein are expressed in the stroma of invasive breast cancers: an in situ hybridization and immunohistochemistry study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Trastuzumab--mechanism of action and use in clinical practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Characterization of a novel primary mammary tumor cell line reveals that cyclin D1 is regulated by the type I insulin-like growth factor receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Current clinical trials of endocrine therapy for breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Use of a transgenic mouse model to identify markers of human lung tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

The transcriptional repressor Snail promotes mammary tumor recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Trastuzumab: triumphs and tribulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Expression of cytochrome P450 2A5 in a glucose-6-phosphate dehydrogenase-deficient mouse model of oxidative stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Expression of IGF-I and IGF-II mRNA in breast tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

RTPrimerDB: the real-time PCR primer and probe database, major update 2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Insulin-like growth factors and neoplasia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Metastasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Function of the IGF-I receptor in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2009.79

31 March 2020

Identifiers

DOI

10.1038/ONC.2009.79

1 reference

Dimensions Publication ID

15 September 2017

1049989034

0 references

1 reference